TaiMed Biologics (TWO:4147) — Stock Price
TaiMed Biologics (TWO:4147) is currently trading at NT$61.00 TWD, up 7.39% today. Over the past 52 weeks, shares have ranged between NT$47.10 and NT$81.80. This page tracks TaiMed Biologics's live share price on the TWO exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see TaiMed Biologics (4147) total market value.
TaiMed Biologics (4147) Stock Price Chart — Daily History & Trading Volume
The chart below tracks TaiMed Biologics's daily closing share price and trading volume on the TWO exchange over the past year, giving a clear view of recent price momentum and liquidity.
TaiMed Biologics Income Statement — Revenue, Profit & Earnings by Year
TaiMed Biologics's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | NT$611.35 Million | NT$610.16 Million | NT$491.78 Million | NT$563.01 Million | NT$413.44 Million |
| Cost of Revenue | NT$351.90 Million | NT$398.94 Million | NT$266.54 Million | NT$347.30 Million | NT$329.49 Million |
| Gross Profit | NT$259.45 Million | NT$211.22 Million | NT$225.23 Million | NT$215.71 Million | NT$83.95 Million |
| Research & Development | NT$381.84 Million | NT$388.21 Million | NT$294.28 Million | NT$333.12 Million | NT$460.60 Million |
| SG&A | NT$72.26 Million | NT$75.29 Million | NT$97.19 Million | NT$74.45 Million | NT$109.72 Million |
| Total Operating Expenses | NT$806.00 Million | NT$862.43 Million | NT$658.01 Million | NT$754.86 Million | NT$899.81 Million |
| Operating Income | NT$-194.65 Million | NT$-252.27 Million | NT$-166.23 Million | NT$-191.86 Million | NT$-486.37 Million |
| EBITDA | — | — | — | NT$-102.74 Million | NT$-306.83 Million |
| EBIT | — | — | — | NT$-191.86 Million | NT$-486.37 Million |
| Interest Expense | NT$10.71 Million | NT$12.60 Million | NT$14.81 Million | NT$10.10 Million | NT$7.44 Million |
| Income Before Tax | NT$-167.78 Million | NT$-201.83 Million | NT$-194.81 Million | NT$-269.29 Million | NT$-470.93 Million |
| Income Tax Expense | — | — | — | — | — |
| Net Income | NT$-167.78 Million | NT$-201.83 Million | NT$-194.81 Million | NT$-269.29 Million | NT$-470.93 Million |
TaiMed Biologics Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes TaiMed Biologics's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | NT$4.81 Billion | NT$5.00 Billion | NT$3.89 Billion | NT$4.10 Billion | NT$4.61 Billion |
| Total Current Assets | NT$3.32 Billion | NT$3.39 Billion | NT$2.15 Billion | NT$2.16 Billion | NT$2.33 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | NT$872.35 Million | NT$1.07 Billion | NT$398.13 Million | NT$371.29 Million | NT$409.27 Million |
| Net Receivables | NT$64.65 Million | NT$83.06 Million | NT$142.89 Million | NT$98.24 Million | NT$157.78 Million |
| Inventory | NT$827.73 Million | NT$998.06 Million | NT$1.27 Billion | NT$1.39 Billion | NT$1.18 Billion |
| Property, Plant & Equipment | — | — | — | NT$957.74 Million | NT$1.01 Billion |
| Goodwill | — | — | — | — | — |
| Total Liabilities | NT$953.05 Million | NT$976.34 Million | NT$1.33 Billion | NT$1.39 Billion | NT$1.67 Billion |
| Total Current Liabilities | NT$253.51 Million | NT$134.76 Million | NT$361.17 Million | NT$329.86 Million | NT$225.08 Million |
| Long-term Debt | NT$440.19 Million | NT$468.03 Million | NT$495.04 Million | NT$521.68 Million | NT$536.00 Million |
| Net Debt | — | — | NT$471.00 Million | NT$461.89 Million | — |
| Total Stockholder Equity | NT$3.86 Billion | NT$4.02 Billion | NT$2.57 Billion | NT$2.71 Billion | NT$2.94 Billion |
| Retained Earnings | NT$-1.30 Billion | NT$-1.14 Billion | NT$-934.55 Million | NT$-740.22 Million | NT$-470.93 Million |
TaiMed Biologics Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how TaiMed Biologics generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | NT$191.14 Million | NT$-379.55 Million | NT$-25.60 Million | NT$-605.21 Million | NT$-211.28 Million |
| Capital Expenditures | NT$22.77 Million | NT$19.35 Million | NT$6.15 Million | NT$3.56 Million | NT$9.69 Million |
| Free Cash Flow | NT$168.38 Million | NT$-398.90 Million | NT$-31.75 Million | NT$-609.97 Million | NT$-224.84 Million |
| Investing Cash Flow | — | — | — | NT$106.11 Million | NT$190.92 Million |
| Financing Cash Flow | — | — | — | NT$208.38 Million | NT$2.79 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | NT$8.77 Million | NT$25.36 Million | NT$10.51 Million | NT$12.27 Million | NT$10.22 Million |
| Depreciation | NT$153.61 Million | NT$154.28 Million | NT$155.39 Million | NT$151.73 Million | NT$152.13 Million |
| Change in Cash | NT$318.15 Million | NT$329.22 Million | NT$-23.10 Million | NT$-277.51 Million | NT$-20.47 Million |
TaiMed Biologics Earnings History — EPS Actual vs. Analyst Estimates
Track TaiMed Biologics's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Mar 12, 2026 | -0.25 | -0.28 | +10.71% |
| Nov 12, 2025 | -0.05 | -0.24 | +79.17% |
| Aug 12, 2025 | -0.22 | -0.13 | -69.23% |
| May 12, 2025 | -0.09 | -0.15 | +40.00% |
| Mar 05, 2025 | -0.44 | -0.17 | -158.82% |
| Nov 13, 2024 | -0.14 | -0.17 | +17.65% |
| Aug 14, 2024 | -0.10 | -0.14 | +28.57% |
| May 13, 2024 | -0.06 | -0.17 | +64.71% |